Sign in

CIK 0001635088

  • Large accelerated filer

Roivant Sciences Ltd.

Sign in to watch
Ticker
ROIV
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Mar 31
Incorporated
Bermuda
Entity type
Operating
EIN
981173944
Phone
+44 12955950
Business address
7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$70,369,463
in 12 filings, $45.5M under 10b5-1 plans

Net −$70,369,463. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-09-27 Ramaswamy Vivek 10% owner Option exercise · Capped Value Appreciation Rights −203,798 $6.40 $1.3M 7,744,314
2023-09-27 Ramaswamy Vivek 10% owner Option exercise · Capped Value Appreciation Rights −251,539 $11.50 $2.9M 11,822,307
2023-09-27 Kumar Rakhi Chief Accounting Officer Option exercise +169 196,716
2023-09-27 Kumar Rakhi Chief Accounting Officer Option exercise · Capped Value Appreciation Rights −1,894 $11.50 $22K 80,020
2023-09-22 Venker Eric President & COO Other disposition −16,416 $10.19 $167K 595,397
2023-09-22 Kumar Rakhi Chief Accounting Officer Other disposition −1,403 $10.19 $14K 196,547
2023-09-22 Gline Matthew CEO Other disposition −11,227 $10.19 $114K 1,033,721
2022-10-16 MOMTAZEE JAMES C Director Grant or award 10b5-1 +1,594 75,456

Page 38 of 38 · 748 trades